Our leadership team has experience from discovery through to commercialisation
Chief Executive Officer
Mr Robert W. Duggan is a serial US based entrepreneur who has built several successful companies across different industries, including biotechnology. Mr Duggan is currently the Chief Executive Officer of Duggan Investment Inc., a private US investment firm. Mr Duggan has served on the boards of a number of US public and private companies and he is currently chairman of the board of the Nasdaq listed company, Pulse Biosciences, Inc. He was previously a substantial shareholder in and the Chairman of the Board and Chief Executive Officer of Pharmacyclics, Inc., which was sold to AbbVie Inc., in 2015. Previously, he was the Chairman of the Board and Chief Executive Officer of Computer Motion, Inc., which later merged with Intuitive Surgical, Inc.
Interim Chief Operating Officer
Dr Elaine Stracker has over 20 years of legal experience for Fortune 500 and start-up life science companies. She currently serves as General Counsel and Senior Vice President for Corporate Development at Maky Zanganeh & Associates Inc., where she assists with due diligence, intellectual property, financings, transactional matters, HR, compliance, litigation, operations and overall strategy development. Previously, Dr Stracker served as General Counsel at Indigo Ag. and at Pharmacyclics, and has held various senior legal counsel positions at Medtronic Inc., Gilead Sciences Inc. Merck & Co., Inc. and Molecular Probes, Inc. (acquired by Invitrogen, Inc.). Dr Stracker earned both a Bachelor’s degree in chemistry and a Doctor of Philosophy degree in organic chemistry from the University of California, Davis. In addition, she earned a Juris Doctorate degree from the Boalt School of Law at the University of California.
Executive Vice President and President of Discuva
Dr Ventzislav Stefanov joined our company in December of 2019 as Non-Executive Director and took executive position in April 2020. Previously he was independent consultant providing advice, including to Duggan Investments Inc, on the therapeutic and commercial prospects of marketed and investigational antibiotics. In his previous tenures, Dr Stefanov held commercial and marketing positions with Bayer, Merck Sharp & Dohme, AstraZeneca and Eli Lilly. He had been involved in launching and marketing across Europe several classes of antibiotics including quinolones, carbapenems, cephalosporins and vancomycin. Dr Stefanov received his MD degree from the Medical University in Sofia, Bulgaria.
Chief Scientific Officer
Dr Dave Powell joined Summit from GSK where he served as Director and Head of the Crick-GSK Biomedical LinkLabs, based at GSK’s UK R&D hub at Stevenage, UK, and The Francis Crick Institute in London.
Dr Powell held a number of positions of increasing seniority in his time at GSK. As part of his work there, he participated in antibiotic discovery, assay development, high throughput screening design and implementation, and lead optimisation support. In his most recent role at GSK, he led a collaboration with the Crick Institute, in addition to providing support to GSK’s ‘Discovery Partnerships with Academia’ team which collaborated with academic groups in downstream drug discovery. He was awarded a BSc and MSc from the National University of Ireland Galway, before completing a PhD in biochemistry at Cardiff University.